SAB Biotherapeutics (SABS) EBITDA Margin (2021 - 2026)
SAB Biotherapeutics (SABS) recorded EBITDA Margin of -8060.15% in Q4 2024, down 2190.06 percentage points from -5870.09% a year earlier.
Powered by 
Analysis
SAB Biotherapeutics (SABS) EBITDA Margin (2021 - 2026) Analysis & Trends
For FY2024, SAB Biotherapeutics reported EBITDA Margin of -2889.02%, down 1353.72 percentage points from FY2023.
- Annual EBITDA Margin has declined for four straight years, with a four-year change of -2926.93 percentage points (FY2020 to FY2024).
- Across earlier years, EBITDA Margin came in at -1535.30% in FY2023 (-1427.72 pp), -107.59% in FY2022 (-88.03 pp), -19.56% in FY2021 (-57.46 pp) and 37.91% in FY2020.
- The Q4 2024 figure is the lowest quarterly EBITDA Margin in data going back to Q1 2021.
- On a year-over-year basis, EBITDA Margin rose in two of the last seven quarters, with an average year-over-year change of -1748.04 percentage points.
- Peak year-over-year performance for EBITDA Margin in the last five years was a gain of 3024.06 percentage points in Q2 2024, against a drop of 6429.77 percentage points in Q2 2023 at the low end.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 36.69% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 46.88% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 40.60% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 39.77% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 46.62% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 50.63% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 42.49% |
| 10 | SAB Biotherapeutics | 279.79 Mn | -130.87 Mn | - | -1,559.51% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -1,559.51% |
| Sep 30, 2025 | -1,953.76% |
| Dec 31, 2024 | -8,029.74% |
| Jun 30, 2024 | -3,488.56% |
| Mar 31, 2024 | -991.83% |
| Dec 31, 2023 | -5,860.33% |
| Sep 30, 2023 | -339.36% |
| Jun 30, 2023 | -6,494.09% |
| Mar 31, 2023 | -1,114.88% |
| Dec 31, 2022 | -319.59% |
| Sep 30, 2022 | -192.01% |
| Jun 30, 2022 | -90.72% |
| Mar 31, 2022 | -51.09% |
| Dec 31, 2021 | -60.43% |
| Sep 30, 2021 | -24.38% |
| Jun 30, 2021 | -14.13% |
| Mar 31, 2021 | 6.45% |
API Access
SAB Biotherapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=SABS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "SABS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=SABS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();